Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

Keytruda's market leadership continues to grow ... And as we said, we would expect to ship about the same amount in the fourth quarter. So you should expect that the fourth quarter itself would ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Italian navy tall ship Amerigo Vespucci is currently docked in Singapore from Oct. 24 as part of its Tour Vespucci world cruise from 2024 to 2025. Members of the public can visit the 101-metre and ...

SINGAPORE - It has been in service since 1931 and looks like it is from another era, with its three huge masts for rigging sails, but the tall ship Amerigo Vespucci is thoroughly modern inside and ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

Indonesia said it deployed two vessels and an aircraft to expel a Chinese ship from contested waters in the South China Sea. The Indonesian National Armed Forces said its Maritime Security Agency ...

The agency said the vessel first entered contested waters on Monday and when an Indonesian ship tried to contact the Chinese boat by radio, the Chinese coast guard said the area was part of Beijing’s ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless of ...